tecovirimat

A potent and specific inhibitor of orthopoxvirus replication. It is used for the treatment of SMALLPOX and other orthopoxvirus infections, including MONKEYPOX under expanded access investigational new drug protocol (https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html).

Also Known As:

4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-benzamide; N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide; SIGA-246; ST 246; ST-246; TPOXX; benzamide, N-((3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(F)isoindol-2(1H)-yl)-4-(trifluoromethyl)-, hydrate (1:1), rel-; tecovirimat monohydrate

Networked: 181 relevant articles (31 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hruby, Dennis E: 28 articles (01/2021 - 01/2007)
2.	Jordan, Robert: 23 articles (03/2013 - 10/2005)
3.	Grosenbach, Douglas W: 11 articles (01/2021 - 02/2008)
4.	Chinsangaram, Jarasvech: 8 articles (01/2021 - 05/2009)
5.	Jones, Kevin F: 8 articles (01/2013 - 02/2008)
6.	Davidson, Whitni: 6 articles (04/2022 - 05/2008)
7.	Tyavanagimatt, Shanthakumar R: 6 articles (03/2013 - 05/2008)
8.	Bolken, Tove' C: 6 articles (09/2012 - 05/2008)
9.	Damon, Inger K: 5 articles (04/2022 - 03/2009)
10.	Honeychurch, Kady M: 5 articles (01/2021 - 07/2012)

Related Diseases

1.	Smallpox (Variola) 12/01/2013 - "Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans. " 12/20/2022 - "Currently approved by the FDA only for the treatment of smallpox, tecovirimat shows promise for the treatment of HMPXV. " 12/01/2013 - "In this study, the efficacy of tecovirimat was evaluated in both a prelesional and postlesional setting in nonhuman primates challenged intravenously with 1 × 10(8) PFU of Variola virus (VARV; the causative agent of smallpox), a model for smallpox disease in humans. " 01/01/2019 - "Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox." 12/01/2013 - "Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)."
2.	Mpox (monkeypox) 01/01/2023 - "However, tecovirimat has the strongest evidence to be effective and safe for monkeypox treatment, and if there is a choice between the two drugs, tecovirimat has shown more promise so far. " 01/01/2023 - "Thus, tecovirimat is expected to be effective against monkeypox. " 12/01/2022 - "The European Medicines Agency (EMA) certified tecovirimat as safe and effective against monkeypox in 2022, per the World Health Organization (WHO). " 02/01/2023 - "Regarding tecovirimat, all two patients recovered from monkeypox. " 11/01/2022 - "The unknown efficacy of tecovirimat against monkeypox."
3.	Vaccinia 01/01/2018 - "Thus, both ST-246 and CDV are of great interest as compounds to treat individuals during Bovine Vaccinia outbreaks in Brazil." 01/01/2012 - "The F13L (p37)-deleted (and ST-246 resistant) vaccinia virus recombinant (Vac-ΔF13L) produced smaller plaques than the wild-type vaccinia (Western Reserve vaccinia). " 01/12/2010 - "After lethal challenge with the Western Reserve strain of vaccinia, Nude, SCID, and J(H) knockout mice additionally depleted of CD4(+) and CD8(+) T cells were not fully protected by ST-246, although survival was significantly extended. " 12/01/2009 - "Treatment with ST-246, a small-molecule inhibitor of virus egress, has been shown to provide protection against severe disease and death induced by several members of the poxvirus family, including vaccinia, variola, and monkeypox viruses. " 01/01/2008 - "Our observations support that vaccinia, cowpox and camelpox viruses exhibit different levels of sensitivity to ST-246 because of dissimilarities between their ways of propagation, and provide a better understanding of the mode of action of ST-246."
4.	Poxviridae Infections 04/01/2007 - "Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection." 01/01/2022 - "ST-246 is an oral drug against pathogenic orthopoxvirus infections. " 09/01/2012 - "ST-246 is being evaluated as a treatment for pathogenic orthopoxvirus infections in humans. " 07/01/2012 - "ST-246, a novel compound that inhibits egress of orthopoxvirus from mammalian cells, is being tested as a treatment for pathogenic orthopoxvirus infections in humans. " 11/01/2010 - "These data support the use of ST-246 as a therapeutic to treat pathogenic orthopoxvirus infections of humans."
5.	Pain (Aches) 01/01/2023 - "Due to severe oral pain, the patient was treated with intravenous tecovirimat 200 mg every 12 h for 4 days with remarkable improvement in lingual lesions. " 11/15/2023 - "Seven out of fourteen patients needed hospitalization due to uncontrolled pain, reduced airspace and difficulty swallowing, of whom five were effectively treated with tecovirimat or cidofovir. " 09/03/2023 - "Nine days after initiating Tecovirimat, the patient presented again with worsening perianal pain and associated hematochezia resulting in acute symptomatic anemia. " 01/01/2023 - "Postexposure prophylactic treatment with a third-generation smallpox vaccine and antiviral agent tecovirimat inhibited local virus spread and alleviated lesion pain." 03/01/2023 - "Here, we present a rare case of a 43-year-old male presenting with excruciating perianal pain and purulent discharge, found to have proctitis secondary to MPX, and subsequently treated with Tecovirimat, a targeted antiviral therapy."

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Cidofovir (Vistide)
3.	tecovirimat
4.	brincidofovir
5.	3- (2- methoxyphenyl)- 5- methoxy- 1,3,4- oxadiazol- 2(3H)- one
6.	Immunoglobulins (Immunoglobulin)
7.	Vaccines
8.	human intravenous vaccinia immune globulin
9.	Smallpox Vaccine (Vaccine, Smallpox)
10.	Intravenous Immunoglobulins (IVIG)

Related Therapies and Procedures

1.	Therapeutics
2.	Treatment Delay
3.	Oral Administration
4.	Aftercare (After-Treatment)
5.	Intravenous Administration